Tests on recalled respiratory devices show limited health risk, says Philips
Philips, a Dutch technology company, on Wednesday said that independent tests on its respiratory devices involved in a major global recall had shown limited health risks. According to a report by the news agency Reuters, Philips rocked investors last year by recalling millions of breathing devices and ventilators used to treat sleep apnea, because foam used to dampen noise from the devices might degrade and become toxic, carrying potential cancer risks. Fears of large litigation bills have since wiped 70 percent off the company’s market value, as per Reuters. On Wednesday morning, Philips shares were up 3.5 percent. “We can state that the whole product complies with safety norms. That is very encouraging news,” Chief Executive Roy Jakobs told Reuters. Philips said the latest tests indicated that exposure to particulate matter emissions from degraded foam in DreamStation devices was “unlikely to result in an appreciable harm to health in patients”, provided the machines had not...
